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Sonoporation is a useful biophysical mechanism for facilitating the transmembrane
delivery of therapeutic agents from the extracellular to the intracellular milieu.
Conventionally, sonoporation is carried out in the presence of ultrasound contrast
agents, which are known to greatly enhance transient poration of biological cell
membranes. However, in vivo contrast agents have been observed to induce capillary
rupture and haemorrhage due to endothelial cell damage and to greatly increase the
potential for cell lysis in vitro. Here, we demonstrate sonoporation of cardiac
myoblasts in the absence of contrast agent (CA-free sonoporation) using a low-cost
ultrasound-microfluidic device. Within this device an ultrasonic standing wave was
generated, allowing control over the position of the cells and the strength of the
acoustic radiation forces. Real-time single-cell analysis and retrospective post-
sonication analysis of insonated cardiac myoblasts showed that CA-free sonoporation
induced transmembrane transfer of fluorescent probes (CMFDA and FITC-dextran)
and that different mechanisms potentially contribute to membrane poration in the
presence of an ultrasonic wave. Additionally, to the best of our knowledge, we have
shown for the first time that sonoporation induces increased cell cytotoxicity as a con-
sequence of CA-free ultrasound-facilitated uptake of pharmaceutical agents (doxoru-
bicin, luteolin, and apigenin). The US-microfluidic device designed here provides
an in vitro alternative to expensive and controversial in vivo models used for
early stage drug discovery, and drug delivery programs and toxicity measurements.
VC 2011 American Institute of Physics. [doi:10.1063/1.3660352]
I. INTRODUCTION
Gas-filled ultrasound contrast-agent microbubbles (UCA or CA) have been used for many
decades in diagnostic imaging as they are effective back-scatterers of ultrasound (US) in per-
fused tissue.1 More recently, CAs are being explored experimentally, both in vitro2 and
in vivo,3 and pre-clinically for their therapeutic potential in the expanding fields of targeted
gene, antibody, and drug delivery.4,5 In particular, at specific ultrasonic frequencies, resonant
CAs are known to drastically enhance transient poration of biological cell membranes
(sonoporation).6
a)Author to whom correspondence should be addressed. Electronic mail: D.Ankrett@soton.ac.uk. Telephone: þ44 (0)
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Sonoporation is a useful biophysical mechanism for facilitating the transmembrane delivery
of therapeutic agents from the extracellular to the intracellular milieu. Other techniques for
facilitating the transmembrane delivery of bioactive molecules include electroporation using
high intensity electric fields to reversibly permeabilize cell membranes,7 microinjection using
micromanipulators and microneedles to inject molecules directly into the cell8 and laser irradia-
tion using a focused laser beam to induce membrane permeabilization.9 However, sonoporation
uses ultrasound to create transient membrane pores and is referred to as a “gentle” technique
for facilitating transmembrane delivery.10
One of the accepted hypotheses is that sonoporation occurs by non-thermal acoustic cavita-
tion, whereby air or gas bubbles under acoustic wave excitation form cavitation nuclei.11 Intrin-
sic formation of “free” gas bubbles within living tissue is rare, with the exception of lung and
intestinal tissue.12 Additionally, free gas bubbles are unstable in liquid and will rapidly dissolve
as a consequence of surface tension at the gas-liquid interface. As such, stabilised CAs (gas
bubbles encapsulated with albumin, galactose, lipid, or polymer shells) are intentionally intro-
duced into tissue to enhance ultrasound back-scatter, yielding high quality imaging.13 Such CAs
are micrometer size (1-10lm diameter) allowing safe medical applications. The dynamic
behaviour of CAs in an ultrasound field is size-, shell-, and gas composition-dependent. Captur-
ing the dynamics of CAs experimentally usually requires high-speed photographic imaging
techniques.14 However, generally at low acoustic pressures CAs oscillate stably (non-inertial
cavitation) but as the driving pressure increases more complex non-linear interactions occur. At
relatively high pressure amplitudes CAs expand in volume, followed by rapid contraction and
“violent” collapse (inertial cavitation). CA collapse has been observed to induce capillary rup-
ture and haemorrhage due to endothelial cell damage in vivo and to greatly increase the poten-
tial for cell lysis in vitro.15 However, CA collapse (also called ultrasound targeted microbubble
destruction or UTMD) is also exploited for local drug and gene delivery. The underlying mech-
anisms involved in delivery are cavitation and formation of microjets creating micropores in
cell membranes by high amplitude oscillations induced by ultrasonic frequencies that are tradi-
tionally used in myocardial contrast echocardiography (MCE).16 UTMD can be applied to any
US accessible or well-perfused tissue; however, cardiac applications are leading this field of
research due to its origin in MCE and accessibility of the heart.17
Cardiovascular drug delivery programs and toxicity measurements generally involve the
sacrifice of many animals. Additionally, cardiac cell isolation is a complex, multi-step pro-
cess.18 Therefore H9c2, a commercially available myogenic cell line derived from embryonic
rat heart ventricle,19 and which has reportedly comparable levels of drug metabolising
enzymes,20 provides a valuable in vitro alternative to the use of rat hearts and thus reducing
reliance on in vivo research. This may contribute, at least in some way, to the 3Rs philosophy
(reduction, refinement, and replacement of animal experiments),21 which is also in line with a
national centred UK government-sponsored scientific organisation, NC3Rs.22
Our experimental work aims to demonstrate the intracellular delivery of pharmaceutical
agents to cardiac myoblasts by non-inertial CA-free sonoporation. An ultrasonic standing wave
(USW) was generated within a biocompatible microfluidic device, which enables high cell via-
bility to be maintained.
The first notable study utilising USW to induce sonoporation was by Khanna et al.23 where
CA was used to induce haemoglobin release from blood cells. Whilst this effect was largely
attributed to cavitation, there were also indications that the cells were being stressed whilst
travelling towards the nodal plane, but only in the presence of CA. Interestingly, Lee and
Peng24 and Rodamporn et al.25 have both reported successful cellular gene transfection by
sonoporation within a USW but in the absence of CA. Lee and Peng attribute their success to
streaming around cells trapped at the nodal plane; however, no direct evidence of streaming
was presented. More recently, Kinoshita and Hynynen26 and Hassan et al.27 have concluded
that USWs increase sonoporation but typically at the expense of viability. However, Rodam-
porn’s detailed study of operating conditions does suggest that careful selection of conditions
can limit loss of viability whilst retaining high transfection rates.25
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Following Rodamporn’s study, we carefully considered the microfluidic device design in
order to provide a low-stress, biocompatible environment for the cells within the ultrasonic
field.28 Microfluidic-based systems offer advantages over conventional bench systems in terms
of performance, reduced sample/solvent quantity, automation, and fine regulation of the bound-
ary conditions.29,30 The micro-scale, in which fluidics is restricted to laminar flow and diffusive
mixing, allows precise control of the physical parameters within the fluidic environment. In
addition, coupling with microscope-based imaging techniques, provides a platform for in situ
analysis of individual cells exposed to US or other physico-chemical stimuli.31,32
Within our device, an USW was generated to induce sonoporation and also to control the
position of the cells. Acoustic radiation forces experienced by the cells move them reliably to
an acoustic pressure node, mid-plane of the fluid chamber, in a single focal plane suitable for
microscope observation. Additionally, our device is an easy-to-use and cost-effective miniatur-
ised system for facilitating drug uptake, and which potentially offers an alternative to more ex-
pensive macro scale systems or animal models, which are routinely used in early stage drug
screening and drug delivery programs. The device also has scope for coupling with other high
resolution technologies and may assist high throughput screening.
To the best of our knowledge, we are the first research team to demonstrate facilitated drug
up-take, resulting from CA-free sonoporation, by cytotoxic measurements pre- and post-
sonications.
II. MATERIALS AND METHODS
CA-free sonoporation [Fig. 1(a)] was investigated by either real-time single-cell analysis or
retrospective post-sonication analysis, using low-, intermediate-, and high- molecular weight
therapeutic agents or fluorescent probes employed as a traceable model of bioactive molecules.
A microfluidic approach, based on a cost-effective and easy-to-use experimental platform, was
adopted to assess CA-free sonoporation of suspended cells.
A. General reagents
Dimethylsulfoxide(DMSO), trypsin-EDTA, trypan-blue (0.4%), MTT (3-[4,5-dimethylthia-
zol-2-yl]-2,5-diphenyltetrazolium bromide, a yellow tetrazolium salt, reduced by mitochondrial
dehydrogenase of viable cells, forming an insoluble intracellular purple formazan product),
FITC-dextran (dextran labelled with fluorescein isothiocyanate), doxorubicin, apigenin, luteolin,
glycerol, foetal calf serum (FCS), Dulbecco’s Modified Eagle’s Medium for cell culture
(DMEM) and penicillin-streptomycin were purchased from Sigma-Aldrich (Dorset, UK). 5-
chloromethylfluorescein diacetate (CMFDA, Cell Tracker Green) and propidium iodide (PI)
were purchased from Invitrogen (Paisley, UK). OptisonTM gaseous CA (3.0-4.5 lm diameter)
was purchased from GE Healthcare (Hatfield, UK). H9c2 cardiac myoblast cells were obtained
from Southampton General Hospital (Southampton, UK).
B. Ultrasonic microfluidic device for CA-free cell sonoporation
The ultrasonic microfluidic device used in this study consisted of a disposable glass micro-
capillary (length: 30mm, width: 6mm, inside height: 300lm, and glass thickness: 300 lm—
VitroCom, Ilkley, UK) acoustically coupled to a piezoelectric transducer (PZT; PZ26 Ferro-
perm, Kvistgard, Denmark) by means of a thin film of glycerol. The transducer (length: 20mm,
width: 6mm, and height: 1mm) was held in place by a poly-methyl methacrylate (PMMA)
spring loaded clamp [Fig. 1(b)] and driven by an RF power amplifier (240 L ENI, Rome, Italy)
fed from a signal generator (TG103 TTI, Cambridgeshire, UK). An USW was generated within
the microfluidic device at a resonant frequency determined through electrical impedance meas-
urements (C-60, impedance analyser, Cypher Instruments Ltd., London, UK). This configuration
allowed cells to migrate towards a nodal plane equidistant from the top and bottom surfaces of
the capillary [Fig. 1(c)].33 All cells flowing through the acoustic environment experience similar
USW levels, as the device design allows spatial averaging. The acoustic pressure (P) within the
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FIG. 1. (a) Schematic representation of the phenomena under investigation. Under normal condition (no US), the cell
membrane is either impermeable or selectively permeable to small- and macro-molecules (i.e., bio-active or probe mole-
cules) (top-left). An USW was applied to cells suspended within the microfluidic environment in the absence of CA. The
ultrasonic wave interacts with cell membrane (US-membrane interaction) through mechanisms that remain widely uninves-
tigated. Both thermal and non-thermal mechanisms may contribute to membrane permeabilization (top-right). US exposure
allows the transmembrane transfer of molecules, occurring through the formation of membrane pores (membrane poration)
(bottom). (b) Microdevice photograph. Cells were injected within the microfluidic device through silicon fluidic connec-
tions and collected in a sterile culture flask. The device was placed on the stage of an inverted microscope. (c) When actua-
tion matched the resonance condition in the capillary (resonance frequency, fR¼ 2.27MHz), a localized standing wave was
generated above the transducer. Acoustic radiation forces experienced by the cells move them reliably to an acoustic pres-
sure node in a single focal plane suitable for microscope observation.
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capillary was measured through a drop-voltage analysis, using 20 lm diameter fluorescent poly-
styrene beads.34 Polyofelin heat shrink tubing was used to stabilize silicon inlet and outlet tub-
ing (1.6mm OD, 1mm ID) for fluid delivery and release [Fig. 1(b)]. All tubing was used with
a minimum length in order to minimize cell sedimentation. A continuous-flow (Qin¼ 0.1
ml/min; Reynolds number, Re¼ 0.53) was established within the microdevice by means of a
syringe pump (KD100, KD Scientific Inc., Holliston) allowing the processing of the relatively
large numbers of cells (0.2 106 cells/min) required for the present study. The continuous-flow
configuration is particularly advantageous for processing large numbers of cells compared with
microinjection and laser configured systems, in which only single cells or low cell numbers can
be processed.35
C. Preparation of cells for ultrasound assays
H9c2 cardiomyoblasts were selected as a biological model to investigate CA-free sonopora-
tion of suspended cells within our microdevice. H9c2 cells were routinely cultured in DMEM
culture medium supplemented with 10% (v/v) foetal calf serum and 1% (v/v) penicillin-
streptomycin. Cells were maintained at 37 C, 5% CO2 in air with 95% humidity.
At 70% confluence (passage range 8-15) H9c2 cells were harvested and cell viability was
determined by trypan blue exclusion. Cell concentration was determined by means of a Neuba-
uer haemocytometer (depth: 0.1mm, area: 0.04 mm2).
D. Temperature monitoring during applied ultrasound
Temperature was measured on the external surface of the PZT transducer by means of a
digital thermometer, while the microdevice was filled with cell culture medium. Recordings
were taken over the range of 0-40V peak-to-peak (Vpp) and at 1min time intervals. Both tem-
perature trend and maximum temperature variation were quantified.
E. Cell viability in the absence (CA-free) and presence of ultrasound contrast agent
Harvested H9c2 cells in serum-free medium were placed in a 1ml syringe at a concentra-
tion of 2 106 cells/ml. Cell viability was established under both static conditions (i.e., cells
seeded directly onto a sterile microtitre well plate) and continuous-flow (inlet flow rate,
Qin¼ 0.1ml/min) at 0, 10, 20, 30, and 40 peak-to-peak voltage (Vpp), in both the presence and
absence (CA-free) of contrast agent. For each amplitude, 1ml of cell suspension was collected
in individual sterile flasks and dispensed (100 ll 6 repeats) with a multichannel pipette into
corresponding rows of the microtitre well plate and incubated at 37 C. Cell viability was deter-
mined by propidium iodide (PI) assay. PI (10lM) was added to the cell suspension and the flu-
orescence intensity (kexc¼ 485 nm, kem¼ 510 nm) was quantified using a FLUOstar Omega
plate reader, and data processed using Omega v. 1.20 and Mars data analysis v. 2.00. For estab-
lishing cell viability in the presence of CA, an average concentration of 33 bubbles/cell was
added to the cell suspension.36 Additionally, acoustic pressure levels employed in the present
study fall into the range of acoustic pressure to which CAs are exposed in vivo.37
F. Single-cell analysis of CA-free cell sonoporation
Single-cell analysis was performed in order to investigate CA-free cell sonoporation using
CMFDA, an intracellular low-molecular size (464.86MW) membrane-impermeable fluorescent
probe. The reduction of intracellular fluorescence intensity was quantified as an indicator of in
situ CMFDA efflux induced by cell sonoporation.
1. Minimisation of CMFDA photobleaching
In order to determine CMFDA efflux induced by CA-free sonoporation, quantification of
superfluous intracellular CMFDA photobleaching was required.
Prior to harvesting, H9c2 cells were incubated with 5 lM CMFDA (in fresh serum free
medium) at 37 C. After 45min, the medium containing CMFDA was aspirated and replaced
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with fresh medium, and cells were incubated for a further 30min to allow cell recovery. Cells
were then harvested and placed in a 5ml plastic syringe and infused into the device. Cells were
imaged in the absence of ultrasound but exposed to fluorescent light (kexc¼ 485 nm). A pulsed
fluorescent light (Dt¼ 1min, synchronized with the CCD camera) at varying exposure times
(texp¼ 150, 200, and 300ms) was applied in order to quantify the photobleaching. The fluores-
cence emitted by intracellular CMFDA was measured by sampling a minimum of 10 individual
cells at each exposure time. Intracellular fluorescence intensity was quantified using an auto-
mated in house MATLAB-based code (The MathWorks Inc., MA).
2. CMFDA efflux by CA-free cell sonoporation
CMFDA loaded cells were injected within the microfluidic device and allowed time to
migrate towards the nodal plane [Fig. 1(c)] prior to imaging. Migration was estimated to be
1-3 s, depending on the excitation voltage. Fluorescent images of single cells were captured
at 1min time intervals, at varying excitation voltages (3.2, 5.6, and 9.2 Vpp). Images at each
voltage were obtained on different days in order to eliminate intracellular CMFDA degradation
over the experimental duration, and voltages were not selected incrementally. After correcting
for photobleaching, intracellular fluorescence intensity was quantified using an in house
MATLAB-based code.
G. Retrospective analysis
1. Drug cytotoxicity comparison pre- and post-sonications
The intracellular delivery of low- (apigenin 270.24 and luteolin 286.24) and intermediate-
(doxorubicin 543.52) molecular weight therapeutic agents, induced by CA-free cell sonopora-
tion, was investigated through retrospective post-sonication analysis. Therapeutic agents include
doxorubicin which has known cardiotoxic activity,38 apigenin which has known cardioprotec-
tive activity39 and luteolin which is a known active metabolite of apigenin.40 The drug concen-
tration (100 lM) was established from a short incubation (4 h, minimum time to allow for cell
adhesion) cytotoxicity curve (data not shown) for apigenin (the least active of the three com-
pounds) in order to identify a concentration that would elicit marginal cell toxicity (IC25) pre-
sonication. This concentration was then applied with luteolin and doxorubicin in order to
observe whether CA-free sonoporation was achievable for structurally diverse drug molecules,
regardless of their initial or intrinsic toxicity.
Harvested H9c2 cells were suspended at a density of 2 106 cells/ml and were placed on
ice until just prior to the addition of either doxorubicin, apigenin, or luteolin. Aliquots (1ml) of
the suspended cells were placed in separate 1ml syringes immediately upon the addition of
each drug, followed by infusion (Qin¼ 0.1ml/min) into the US device. Following infusion, sam-
ples (exposed to either, 0, 10, 20, 30, or 40 Vpp) were recaptured in sterile containers and dis-
pensed into a microtitre well plate. Controls consisted of either cells seeded directly into the
microtitre well plate, cells infused into the device in the absence of drug, or cells infused into
the device in the absence of both drug and US. All cells were subsequently incubated for 4 h to
allow cell adhesion, followed by a further 1.5 h incubation in the presence of MTT (50 ll of
1mg/ml solution). All medium was then aspirated and the resulting MTT formazan product
was solubilised in 150 lM of DMSO. MTT absorbance (kabs¼ 540 nm) was quantified using a
FLUOstar Omega plate reader, and data processed using Omega v. 1.20 and Mars data analysis
v. 2.00.
2. CA-free ultrasound-induced FITC-dextran uptake
The intracellular delivery of high-molecular weight FITC-dextran fluorescent probe
(40 kDa), induced by CA-free cell sonoporation, was investigated through retrospective post-
sonication analyses.
Harvested H9c2 cells were placed in 1ml syringes containing 0.5ml cell serum-free me-
dium and 0.5ml of 0.25mg/ml (final concentration) FITC-dextran, in sterile phosphate buffer
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and with a cell concentration of 2 106 cells/ml. Control cells were incubated at room tempera-
ture with FITC-dextran, in the absence of ultrasound. Experimental cells were infused into the
device at Qin¼ 0.1ml/min. Intracellular FITC-dextran was quantified by measuring sample ab-
sorbance at kabs¼ 490 nm, using a FLUOstar Omega plate reader. Data were processed using
Omega v. 1.20 and Mars data analysis v. 2.00.
III. RESULTS AND DISCUSSION
A. Microfluidic device characterisation
An USW was generated within the microfluidic device. Electrical impedance measurements
showed a minimum in the impedance spectrum at the resonant frequency (fR) of 2.27MHz
(data not shown), which was subsequently selected as the working frequency. Impedance meas-
urements were repeated prior to each experiment to ensure consistent operating conditions, and
only slight variations in resonant frequency (DfR¼60.03MHz) were observed over the course
of the experiments described here.
The acoustic pressure (P) within the capillary, measured through drop-voltage analysis,
was calculated to be 3.47 104Vpp Pa, with the excitation voltage, Vpp, varying between 3.2
and 40 Vpp. This corresponded to pressures in the range of 0.11–1.39MPa.
The US environmental temperature was monitored to ensure that biologically compatible
temperatures were maintained. Figure SI1(a) in the supplementary information41 shows temper-
ature recordings over 0–15min. At 10 Vpp the temperature increased gradually from ambient,
varying between 21 and 23 C, up to 25 C over the first 6min then plateaued. Long-term
(tend¼ 4 h), this plateau was maintained until recording ceased. However, at 30 Vpp the tempera-
ture increased more steeply from ambient, reaching a plateau at  38 C [inset, Fig. SI1(a) in
the supplementary information41]. Therefore, it is reasonable to assume that thermal mecha-
nisms do not contribute to either cell sonoporation or reduced cell viability at the lower Vpp
employed in the present study. However, the contribution of thermal mechanisms42 on mem-
brane poration or cell viability cannot be completely excluded at the higher voltages.
Whilst US-induced increase of the local temperature has been already reported as a poten-
tial facilitating agent of cell membrane permeabilization,43,44 the contribution of temperature
elevation on the formation of transmembrane pores remains unclear.45
B. Cell viability in the absence (CA-free) and presence of ultrasound contrast agent
A comparison of cell viability in both the absence and presence of CA (Fig. 2) revealed
that at lower amplitudes (Vpp 20) no significant difference in viability between CA-free and
CA-based US exposure was observed. However, at higher amplitudes (Vpp> 20) viability was
significantly reduced in the presence of CA, in agreement with Chen et al.46 This is maybe due
to the increased cavitation activity associated with CAs.46,47 Cell viability following US-
induced membrane poration in the absence of CA remains largely overlooked and as such, cell
viability is generally reported in terms of the combined effect of US with CA rather than the
effects of US “alone.”48 Additionally, commercially available CAs appear to have varying
threshold levels before inducing cell death.49 Cell death mechanisms (apoptosis, necrosis, auto-
lysis, autophagy, and oncosis) display considerable overlap,50 adding further complexity. There-
fore, further research is required in order to delineate the concomitant contribution of CA and
US on cell viability and the way in which they bring about cell death.
C. Single-cell analysis: Real-time intracellular CMFDA efflux induced by CA-free cell
sonoporation
1. Minimisation of CMFDA photobleaching
In order to quantify sonoporation by efflux measurements of the fluorescent probe CMFDA
from the intracellular to the extracellular environment, the fluorescence photobleaching of
CMFDA was firstly quantified.41 At three different fluorescent exposure times (texp¼ 150, 200,
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and 300ms) photobleaching showed a linear-like trend (data not shown). Experimental data
were averaged and linearly interpolated (R2> 0.95 in all cases). The absolute value of the inter-
polation slope (defined as a bleaching coefficient, b) was observed to linearly vary with texp,
with higher exposure times producing enhanced bleaching [Fig. SI1(b) in the supplementary in-
formation41]. Additionally, b showed that the rate of CMFDA photobleaching was slower than
the rate of CMFDA efflux by sonoporation, thus quantitative sonoporation was possible.
2. CMFDA efflux by CA-free sonoporation
The dynamics of CA-free single-cell sonoporation was evaluated by measuring the real-
time reduction of intracellular fluorescent CMFDA at 3.2, 5.6, and 9.2 Vpp. However, despite
consistent US operating conditions, this reduction in fluorescence consistently showed two re-
producible temporal trends [Fig. 3(a)] throughout the range of Vpp investigated. The trends
were assigned as exponential-like (Group A) and parabolic-like (Group B) [Fig. 3(a)]. The aver-
age interpolation functions were determined as follows (R2 was> 0.9 in all cases examined):
FInorm tð Þ ¼ eKA t ðGroupAÞ; (1)
FInorm tð Þ ¼ KBt2 þ C1tþ 1 ðGroupBÞ; (2)
where FInorm is the intracellular fluorescence intensity normalised to the initial value, FI(0); t is
the time (minutes); C1 is a numeric constant; KA and KB are parameters assumed here as indica-
tors of sonoporation dynamics (i.e., CMFDA efflux) for cells located in Group A and Group B,
respectively. KA was observed to increase significantly by increasing the applied Vpp from 3.2
to 5.6 (KA¼ 0.164min1 and 0.212min1 at Vpp¼ 3.2 and 5.6, respectively); however, only a
marginal increase was detected by further increasing the Vpp (KA¼ 0.212min1 and
0.231min1 at Vpp¼ 5.6 and 9.2, respectively) [Fig. 4(b)]. KB instead showed a significant
increase only at Vpp¼ 9.2 (in respect to lower amplitudes) [Fig. 4(b), blank circle].
The reason for the emergence of these two trends is unknown; however, a theoretical
model proposed by Krasovitski et al. may explain the experimental observations.51 The
FIG. 2. H9c2 cell % viability measured in the absence (blank circle) and in the presence (filled square) of CA. Data at 0,
10, 20, 30, and 40 Vpp are reported (n¼ 6 at each Vpp). At Vpp 20 CA-free and CA-based cell viability display similar val-
ues. At Vpp> 20 CA-free and CA-based cell viability diverge, with CA-free US exposure maintaining higher viability,
compared with CA-based US exposure.
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exponential-like decay may correspond to an immediate short-term response of the cell mem-
brane upon initial US exposure, potentially leading to sudden membrane permeabilization. Kra-
sovitski’s model suggests that large membrane strain thresholds are reached immediately after
US exposure commences (at 0.2 and 0.8MPa acoustic pressures), due to a vibrational mecha-
nism described as intramembranous cavitation.51 Notably, the acoustic pressure exerted on the
cell membrane within our microdevice (in the range of 0.11-1.39MPa) whilst travelling towards
the nodal plane,52 may be among the potential mechanisms leading to the observed short-term
membrane poration resulting in the exponential-like efflux of CMFDA.
Our findings show that short-term CA-free membrane sonoporation occurs at relatively low
Vpp [Fig. 4(a)] and that by increasing Vpp results in a non-linear increase of short-term sonopo-
ration rate [Fig. 4(b), filled circle]. In this respect, we can hypothesise that over a critical Vpp
CA-free short-term sonoporation dynamics remains substantially unvaried, and CMFDA efflux
is regulated by passive diffusion through transmembrane pores.
Conversely, an explanation for long-term membrane response has not been put forward so
far. However, we hypothesize that the parabolic-like CMFDA efflux may be the result of such
long-term membrane response to US. This hypothetical long-term response may be induced by
FIG. 3. Fluorescent microscopy-based analysis of CMFDA efflux from H9c2 cells. (a) Intracellular normalized fluores-
cence intensity of CMFDA at time intervals of 1min (USW exposure¼ 6min). CA-free sonoporation induces the transfer
of CMFDA from the intracellular to the extracellular milieu (inset). Reduction in intracellular fluorescence shows a bi-
phasic cell response. The two characteristic trends are reported: Group A (exponential-like, filled square) and Group B (par-
abolic-like, blank circle), at 9.2 Vpp (n¼ 10 at each Vpp). (b) Representative microscope fluorescent images
(50magnification) at 0, 3, and 6min (Vpp¼ 9.2).
044108-9 Contrast-agent free sonoporation Biomicrofluidics 5, 044108 (2011)
Author complimentary copy. Redistribution subject to AIP license or copyright, see http://bmf.aip.org/bmf/copyright.jsp
a fatigue condition generated by the periodic expansions and contractions of the membrane leaf-
lets, which is in agreement with Krasovitski’s intramembranous cavitation concept. This cyclic
intramembranous strain condition may be responsible for the formation of transmembrane pores
that occurs only after the cell membrane is subjected to a critical number of strain cycles.
Experimental observations suggest that the dynamics of long-term CA-free sonoporation
varied significantly only at Vpp higher than a critical value (i.e., Vpp> 5.6 in our microdevice)
[Fig. 4(b)], thus implying the existence of interplay between the number of strain cycles and
the absolute value of membrane strain (which will depend on the applied Vpp). In addition, the
onset of non-inertial streaming53 at the nodal plane (experimentally observed at Vpp> 7) may
contribute to additional fluid shear stress on the cell membrane, thus enhancing or facilitating
long-term membrane response described above. Until further research is undertaken, the
observed bi-phasic dynamics of membrane CA-free sonoporation can only be explained theoret-
ically. Krasovitski’s intramembranous cavitation model provides a good conceptual correlation
with our experimental observations, but further experimental assessment is required.
3. Average CMFDA efflux dynamics
The average reduction of intracellular CMFDA fluorescence intensity (DFInorm) with respect
to the applied Vpp was measured at 2, 4, and 6min from the onset of US exposure (Fig. 5). The
results show that, at 3.2 Vpp, longer US exposure times (t 2min) were required to initiate a
measurable reduction of CMFDA by CA-free cell sonoporation (DFInorm¼ 0.27 after 6min). In
contrast, at 5.6 and 9.2 Vpp, a more significant reduction of intracellular CMFDA was observed,
and over shorter US exposure times (DFInorm¼ 0.35 and 0.41, respectively, after 4min). Addition-
ally, DFInorm was observed to saturate with increasing Vpp (a non-linear relationship occurred
between DFInorm and Vpp) (Fig. 5).
A representative average trend of the intracellular CMFDA fluorescence intensity (FInorm),
at Vpp¼ 5.6, is shown in the inset of Figure 5. Fluorescence data are plotted together with the
corresponding standard deviation and control trend (established from photobleaching measure-
ments). An analytical formulation was established in order to describe the average FInorm-t
relationship
FInorm ﬃ 1 for t  t0; (3)
FInorm ¼ KT 	 tþ C2 for t  t0; (4)
where t0 is equal to 0, 1, and 2min for Vpp of 9.2, 5.6, and 3.2, respectively; C2 is a numeric
constant; KT is equal to 0.12, 0.11, and 0.08min
1 for Vpp of 9.2, 5.6, and 3.2 respectively, and
represents a quantitative estimation of the average CMFDA efflux dynamics, depending on the
FIG. 4. Real time, single cell analysis of the dynamics of US-induced CMFDA efflux by H9c2 cells, in the absence of CA.
CMFDA transfer from the intracellular to the extracellular milieu showed two distinct reproducible trends. (a) Percentage
of cells in Group A and Group B, at three different Vpp. CA-free sonoporation dynamics is quantified by calculating KA
(min1) and KB (min
2) values, at different Vpp (b); n¼ 10 at each Vpp. Both KA and KB increased with increasing Vpp.
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mutual contribution of CA-free short-term sonoporation and CA-free long-term sonoporation !
KT¼KT(KA,KB).
The results show that intracellular CMFDA fluorescence remained approximately constant
( 1) until a critical time instant (t0), and decreased following a linear-like function (R2> 0.95)
for t> t0; where t0¼ t0(Vpp). The average CMFDA efflux rate was observed to increase non-
linearly with the applied voltage. These observations are supported by the Vpp-dependence of
both long-term and short-term sonoporation dynamics, illustrated in Figure 4(b), with higher
voltages favouring short-term mechanisms [Fig. 4(a)].
These results suggest that higher Vpp provide efficient ultrasonically induced efflux of
CMFDA (Fig. 5). However, the efficiency of CMFDA efflux (DFI) is subjected to saturation
(and likely the mass transfer of similar molecules) and any further increase of Vpp over the sat-
uration limit risks compromising cell viability.
Notably, the efficiency of mass transfer will also vary according to the device design and
physical ultrasonic parameters (i.e., working frequency), which require characterization for a
given device configuration.
D. Retrospective analysis
1. Drug cytotoxicity comparison pre- and post-sonications
The CA-free ultrasound induced uptake of doxorubicin, apigenin, and luteolin was observed
to be facilitated by measuring their respective cytotoxic action pre- and post-sonications.
Retrospective analysis of cell cytotoxicity (measured by traditional MTT assay) in the pres-
ence of doxorubicin both pre- and post-sonications [Fig. 6(a)] showed that doxorubicin cytotox-
icity increased by 25%, 55%, 91%, and 85% post-sonication at 10, 20, 30, and 40 Vpp, respec-
tively, in respect to doxorubicin in the absence of US. In the presence of apigenin, cytotoxicity
increased by 2%, 24%, 40%, and 50% post-sonication at 10, 20, 30, and 40 Vpp, respectively,
in respect to apigenin in the absence of US [Fig. 6(b)]. The cytotoxicity of luteolin, an active
metabolite of apigenin, increased by 15%, 83%, 89%, and 90% post-sonication at 10, 20, 30,
and 40 Vpp, respectively, in respect to luteolin in the absence of US [Fig. 6(c)].
Cytotoxicity-Vpp relationship was investigated by introducing a coefficient (cytotoxic coeffi-
cient, Cyt) defined as: 1-[cs(Vpp)/cs(control)], where cs(Vpp) corresponds to cell survival (in %)
measured at a given Vpp, and cs(control) corresponds to cell survival (in %) measured at 0 Vpp
FIG. 5. Evaluation of CMFDA efflux by single-cell analysis. The average reduction of intracellular fluorescent intensity
(DFInorm) at 3.2, 5.6, and 9.2 Vpp is shown. DFInorm values at 2, 4, and 6min from the onset of the USW are reported. A
representative intracellular fluorescence (FInorm) decay is also shown (inset), corresponding to Vpp¼ 5.6. n¼ 10 at each
Vpp.
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in the absence of both US and drugs. Figure 6(d) shows the experimental Cyt values at different
Vpp together with the interpolation curve (spline interpolation). The results show that CA-free
sonoporation induced an increase in the cytotoxic action of doxorubicin, apigenin, and luteolin
suggesting that the uptake was facilitated with respect to toxicity occurring through passive dif-
fusion [Figs. 6(a)–6(c)]. Cyt showed a non-linear dependence on the applied voltage where cy-
totoxic action increased with increasing Vpp until a plateau level was reached, which is in
agreement with our single-cell analyses. The observed plateau could be attributed to either
mass transfer saturation (as observed in single-cell experiments) or a biological effect such as
enzyme inhibition due to active site saturation.
These results indicate that by increasing Vpp above 30V does not further facilitate drug
uptake and may also potentially compromise cell viability.
2. CA-free ultrasound-induced FITC-dextran uptake
The delivery of a high-molecular weight fluorescent probe (FITC-dextran, 40 kDa) induced
by CA-free sonoporation was investigated. Figure 7 shows the percentage of intracellular FITC-
dextran at different 0, 10, 20, 30, and 40 Vpp. In order to quantify intracellular FITC-dextran
only, absorbance of the extracellular FITC-dextran (in medium) was quantified and subtracted
from the total absorbance of the sample. Controls in static conditions and continuous-flow were
undertaken in order to assess the contribution of spontaneous diffusion and of flow shear stress
on FITC-dextran mass transfer, respectively (inset, Fig. 7). The results show that marginal dif-
fusion occurred due to the effect of flow shear stress on the cell membrane (inset, Fig. 7).
An increase in intracellular FITC-dextran with increasing Vpp was also observed (Fig. 7).
However, a significant increase was only evident at Vpp> 20, further corroborating the observed
FIG. 6. The facilitated uptake of pharmaceutical agents, from the extracellular to the intracellular environment, was quanti-
fied through cytotoxicity measurement. Percentage of cell survival was quantified as an indicator of cell uptake of doxoru-
bicin (a), luteolin (b), and apigenin (c); at 0, 10, 20, 30, and 40 Vpp. Controls corresponded to 0 Vpp and no extracellular
drug; n¼ 6 at each Vpp. (d) Cyt-Vpp relationship was plotted for each drug, showing that, although each drug displays differ-
ent initial (no US) cytotoxicity, the toxicity in all cases increased with increasing Vpp. Control cells in the absence of drug
are shown by dotted line.
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non-linear dependence of mass transfer efficiency on the applied Vpp. Furthermore, the results
show that high-molecular weight FITC-dextran required higher Vpp to be delivered intracellu-
larly by CA-free sonoporation, compared to the relatively smaller agents, apigenin, luteolin, or
doxorubicin, suggesting a complex interrelationship between the efficiency of mass transfer,
pore size, and the applied Vpp. CA-free sonoporation within our microfluidic device allowed the
transmembrane transfer of high-molecular weight molecules, having comparable size with bio-
active macromolecules such as DNA fragments, siRNA, and proteins.
IV. CONCLUSIONS
CA-free cell sonoporation was investigated by generating an USW within a microfluidic
device. Both real time single-cell analysis and retrospective post-sonication analysis revealed
successful transmembrane transport of differently sized molecules, without the need for expen-
sive contrast agents and thus avoiding the associated cavitational effects which significantly
compromise cell viability. This microfluidic-based strategy allowed fine control of the fluidic
environment (i.e., low Reynolds number), whilst the USW allowed precise regulation of the US
stimulus and in situ microscope-based monitoring of individual cells located at the nodal plane.
In addition, the continuous-flow condition allowed for the processing of relatively large num-
bers of cells without exerting significant additional stress on the cell membrane.
Crucially, by combining these strategies, we were able to demonstrate, for the first time,
the facilitated up-take of potentially beneficial pharmaceutical agents by cytotoxic measure-
ments both pre- and post- sonications. In the current economic climate this low-cost US-micro-
fluidic device provides an alternative to other more expensive techniques for transmembrane
drug delivery, such as laser irradiation.35 Additionally, our strategy provides an in vitro alterna-
tive to controversial in vivo models used for early stage drug discovery, drug delivery pro-
grams, and toxicity measurements.
Interestingly, single-cell analyses within our microfluidic device have suggested the exis-
tence of different biophysical mechanisms contributing to US-induced membrane response in
the absence of CA. In this regard, further studies are currently under investigation in our
FIG. 7. Transmembrane transfer of FITC-dextran (40 kDa) induced by CA-free sonoporation. Intracellular FITC-dextran
% at 0, 10, 20, 30, and 40 Vpp is shown. The comparison between static condition and continuous-flow condition (no US)
(inset 1) shows that the contribution of fluid-shear stress on transmembrane transfer of FITC-dextran was observed and was
negligible. Representative microscope images (20magnification) of a single suspended H9c2 cardiomyoblast (inset 2(a),
bright field image; 2(b), fluorescent image) are shown after CA-free sonoporation at 30 Vpp; n¼ 4 at each Vpp.
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laboratories in order to gain a deeper understanding of the mechanisms regulating CA-free cell
sonoporation; an area that has been largely overlooked since most sonoporation studies include
CA. As such it has been difficult to precisely delineate US effects from CA effects on cell via-
bility and membrane stress response. We will also be investigating ways of coupling our US
microfluidic-based device with high throughput screening systems and high-resolution bio-ana-
lytical methodologies.
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